Across TCGA pan-cancer cohorts, MVK Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MVK data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MVK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MVK expression acts as an unfavorable survival marker.
STAD and PRAD are the cancer types where MVK Mutation most reproducibly stratifies survival.